MicroRNAs (miRNAs) are associated with cytogenetics and molecular subtypes of acute myelogeneous leukemia (AML), but their impact on AML pathogenesis is poorly understood.
Introduction
Acute Myeloid leukemia (AML) is a heterogeneous disorder which includes many entities with diverse genetic abnormalities and clinical features. 1 In addition to specific chromosomal translocations, deletions and amplifications (eg. t (15;17) , -5q, -7q ,+8), the discovery of gene mutations (eg. FLT3-ITD, CEBPA, NPM1) and oncogene deregulation (ERG and BAALC overexpression) have improved the molecular and prognostic classification of AML, in particular for patients with cytogenetically normal AML (CN-AML). 2 Over the past few years, a new class of small non coding RNAs, named microRNAs (miRNAs), has changed the landscape of human genetics. Evolutionarily conserved, miRNAs are 18-24 nucleotides (nt) in length that regulate gene expression for the most part, by targeting mRNAs according to the degree of complementarity with their 3' untranslated region (UTR). 3 MiRNAs are involved in the regulation of critical biological processes, including cell cycle, differentiation, development, and apoptosis. [4] [5] [6] [7] Recent data indicate that miRNAs are deregulated in diseases, such as diabetes, heart disease and cancer. [8] [9] [10] Our group and others have reported unique miRNA profiles associated with the main cytogenetic and molecular subgroups of AML. [11] [12] Despite this progress, very few mechanistic studies have been carried out to dissect the functional role of miRNAs in AML.
The miR-29 family is comprised of three isoforms arranged in two clusters; miR-29b-1/miR-29a located on chromosome 7q32 and miR-29b-2/miR-29c located on chromosome 1q23.
Interestingly, chromosome 7q32 is a region frequently deleted in myelodysplastic syndromes (MDS) and therapy related AML. 13 MiR-29 family members have been shown to be downregulated in high risk chronic lymphocytic leukemia (CLL), lung cancer, invasive breast cancer, and cholangiocarcinoma. [14] [15] [16] [17] The enforced expression of miR-29b induced apoptosis in
For personal use only. on July 15, 2017 . by guest www.bloodjournal.org From cholangiocarcinoma cell lines and reduced tumorigenicity in a xenograft model of lung cancer and rhabdomyosarcoma. [17] [18] [19] We reported that expression of miR-29 family members is downregulated in primary AML samples with chromosome translocations involving fusion of the MLL1 gene, in particular with the t(6;11) and t(9;11) translocations. 11 In addition, primary CN-AML samples with wild type nucleophosmin gene (NPM1) have low levels of miR-29s compared to CN-AML samples with NPM1 mutations.
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In this study, we explored the functional role of miR-29b in AML. We report that overexpression of synthetic miR-29b in AML cell lines and primary AML blasts induced apoptosis.
Direct inoculation of synthetic miR-29b oligonucleotides into xenograft tumors dramatically decreased tumor growth. The data support a miR-29b tumor suppressor function and provide a rationale for the use of synthetic miR-29b oligonucleotides as a novel therapeutic agent in AML.
Methods
Patients Samples. Frozen diagnostic bone marrow (BM) or peripheral blood (PB) samples were obtained from 100 adult AML patients from the MD Anderson Tissue bank. Patient's samples were prepared by Ficoll-Hypaque (Nygaard) gradient centrifugation, enriched for leukemic cells by CD3/CD19 depletion using MACS (Miltenyi Biotech, Auburn, CA) and cryopreserved as previously described. 11 Cytogenetic analyses of the samples were performed at diagnosis, using unstimulated short-term (24-, 48-, and 72-hour) cultures with or without a direct method and G-banding. The criteria used to describe a cytogenetic clone and description of karyotype followed the recommendations of the International System for Human Cytogenetic
Nomenclature. 21 At least 20 bone marrow metaphase cells were analyzed in patients designated
For personal use only. on July 15, 2017 . by guest www.bloodjournal.org From as having a normal karyotype. FLT3-ITD, activation loop D835 and NPM1 mutations analysis was performed on most of the samples as previously described. 20 All patients gave informed consent in accordance with the Declaration of Helsinki for cryopreservation and use of the samples for molecular studies. Approval was obtained from the institutional board review from the MD Anderson Cancer Center.
Microarrays experiments. RNA extraction and miRNA microchip experiments were performed as described in detail elsewhere 11 . Five micrograms of total RNA was used for hybridization on the custom miRNA microarray chip (OSU_CCC version 3.0) which contains ≈ 1,100 miRNA probes, including 345 human and 249 mouse miRNA genes, spotted in duplicates. For gene-expression profiling, RNA samples were analyzed with the use of Affymetrix U133 plus 2.0 GeneChips (Santa Clara, CA).
Northern Blotting. Northern Blotting was performed as previously described. 14 Briefly, total RNA was extracted using Trizol reagent (Invitrogen, Carlsbad, CA). RNA samples (10 ug) were run on 12% polycramide denaturing (urea) precast gels (BIO-RAD, Hercules, CA) and then transfered onto Hybond membrane (Amersham Pharmacia Biotech, Uppsala, Sweden). The hybridization was performed with α -32P miR-29a and -b labeled probes overnight at 42º. The miR-29 probes sequences were the complementary one to the mature miR-29s. As a loading control we measured U6 expression after stripping the filter as previously described.
14 Real-Time quantification of miRNAs. The single tube TaqMan miRNA assays were used to detect and quantify mature miRNAs as previously described 22 using PCR 9700 Thermocycler ABI Prism 7900HT and the sequence detection system (Applied Biosystems, Foster City, CA). Data Analysis. miRNA microarray images were analyzed using GENEPIX PRO. Average values of the replicate spots of each miRNA were background subtracted; log2 transformed and normalized using the global median and the BRB array tools (http://linus.nci.nih.gov/BRBArrayTools.html).For the affymetrix experiments, Cel. Files generated by the GeneChip scanner were imported to the BRB software tools. GCRMA procedure was used for background subtraction and normalization. A filtering step was performed to remove probe sets that did not show significant variation across the samples: a probe was excluded if less than 20 % of expression data have at least a 1.5 -fold change in either direction from gene's median value or the percent of data missing or filtered out exceeds 50 % . Class comparison within the BRB tools was used to compare mRNA expression after transfection of synthetic miR-29 vs. scrambled oligonucleotides in K562 cells. To identify mRNAs that correlated with miR-29a and -29b expression in AML patients we performed quantitative trait analysis (Spearman correlation test) using the BRB tools. The miR-29a and -b expression values for each patient were obtained using miRNA microarrays as described above. Only normalized, log2 values were used. All the analyses were performed using BRB-ArrayTools version 3.6.0 (R. Simon and A.P. Lam, National Cancer Institute, Bethesda, MD) and using the R version 2.3.1 (R Foundation for Statistical Computing, Vienna, Austria). To asses whether certain biological terms were enriched or over-represented in a signature, we used the Database for Annotation, Visualization and Integrated Discovery (DAVID) http://david.abcc.ncifcrf.gov/. 24 In our analysis, we used high Statistical analysis. Both t-test and chi-square were used to compare baseline clinical features and average miRNA expression between groups of patients. All reported P-values were twosided and obtained using the SPSS software package (SPSS 15.0). Some graphics were performed using GraphPad prism software (www.graphpad.com).
In vitro transfection with synthetic miRNAs. The synthetic miR-29a and -29b, were purchased from Ambion (Austin, TX). Five millions of K562 cells (ATCC, Manassas, VA) were nucleoporated using AMAXA (Solution V, Program T016) (Gaithersburg, MD) with 5 ug of precursor oligonucleotide and 0.5 ug GFP plasmid in a total volume of 10 ml. The transfection efficiency of K562 cells using this method is close to 90% (www.lonzabio.com and Figure S1 ).
The synthetic miR-212 was used as an additional control in the K562 experiments. This miRNA is not expressed in primary AML samples or in hematopoietic stem cells. [11] [12] MiR-29s expressions levels, before and after transfection, are shown in Figure S1 . Primary bone marrow or peripheral blood samples from 3 newly diagnosed AML patients were obtained after getting inform consent according to the MD Anderson Cancer Center IRB guidelines. Two patients had normal cytogenetics with wild type NPM1 and FLT3, while the other patient had t(9;11). After
Phicoll preparation, the samples were enriched for leukemic cells by CD3/CD19 depletion.
Approximately 3x10 6 primary AML blasts were nucleoporated with synthetic miR-29b or scrambled oligonucleotides (AMAXA, program T020, solution V). The expression of the oligonucleotides after transfection was assessed by qRT-PCR as described before ( Figure S2 ). Cell Growth curve. K562 (5x10 5 /ml) were plated in 10 ml plates and transfected with scrambled or miR-29s oligonucleotides from Ambion at a final concentration of 100 nM, using nucleoporation as previously described. Kasumi-1 (8x10 5 /ml) cells were plated in 10 ml plates and infected with miR-29a and -29b lentivirus or control (empty lentivirus) as previously explained. Cells were harvested and counted at 24-h intervals by using a ViCell counter (Beckman Coulter, Fullerton, CA 
Results

MiR-29 reduces cell growth and induces apoptosis in cell lines and primary AML samples
To examine the biological effects of miR-29a and -29b in AML, we over expressed both miRNAs in two myeloid leukemia cell lines (K562 and Kasumi-1) and examined cell growth curves and apoptosis. Both cell lines were chosen because they expressed low miR-29a and -29b levels ( Figure S1 ). Synthetic miR-29a and -29b oligonucleotides as well as two controls (scrambled oligonucleotides and miR-212) were transfected into K562 cells using nucleoporation. Because of low efficiency and high mortality of Kasumi-1 cells with nucleoporation methods, we used a lentivirus construct to over-express miR-29s. The empty lentivirus was used as a control ( Figure S3 ). As shown in Figure 1A , over-expressing both miRNAs inhibited the cell growth of K562 and Kasumi-1 cell lines with respect to their respective controls. These results were validated using the MTT test ( Figure S4 ). Next, we examined the effects of these miRNAs on apoptosis. In Figure 1B , we showed that miR-29b over-expression increased apoptosis at 48 hours (no effects were observed at 24 hours) by 3. For personal use only. on July 15, 2017. by guest www.bloodjournal.org From E). Last, we confirmed these results in two primary AML samples that were transfected with synthetic miR-29b or scrambled oligonucleotides and treated with ARA-C (5uM) or control (PBS) ( Figure 1F ). We found a 1.4 fold increase in apoptosis after synthetic miR-29b transfection, with respect to scrambled oligonucleotides. The anti-apoptotic effects of miR-29b in primary AML samples are not as strong as in the one observed in the cell lines, in particular after ARA-C treatment. This could be explained by the high nucleoporation toxicity observed in primary AML samples.
Effects of miR-29b overexpression in a xenograft model
As further proof that miR-29b functions as a tumor suppressor, we tested whether miR-29b Table S1 ). Genes found de-regulated in K562 cells after transfection of miR-29a
and -29b were analyzed with DAVID functional analysis software to identify the most represented gene ontology (GO) categories. 24 These results are shown in Table S2 online. In particular, genes related to apoptosis (MCL-1, TRAF4, MYBl2) and cell cycle regulation (CDK4, (Table S1 ). Although, not over-represented in any GO class, few genes down-regulated after miR-29s transfection are genes involved in cell proliferation pathways such as JAK2 and IGF1. Together these data indicate that miR-29a and29b target apoptosis, cell cycle and cell proliferation pathways.
MiR29a and -29b predicted targets are specifically and significantly down-regulated after miR-29s transfections.
To investigate whether miR-29 regulated predicted targets we performed a class comparison analysis (scrambled oligonucleotides versus pooled miR-29a and -29b transfections) using, instead of the whole genome, a subset of 602 genes which are predicted targets according to TargetScan. 25 By using the same stringency of the whole genome test (P<0.001) we identified up-regulation of 5 probe-sets (2 genes) and concomitant reduction in expression levels of 92 probe-sets (68 genes) ( Table S3 ). The Box plots in supplemental figure 3B display the median and standard deviation of the t-test scores for either all 602 targets of miR-29 and all other expressed non-targets genes. When the number of up and down-regulated genes were compared in a 2x2 table, it was apparent that miR-29a and -29b transfections specifically down-regulated mRNA levels of the predicted targets (Yates Chi square=22, P<0.001). Significant miR-29 targets down-regulation (Yates Chi square=22, P<0.001) was also found by using a different prediction algorithm, PicTar. 26 Among the miR-29b predicted targets down-regulated after miR29s transfections, COL1A2 and DNMT3B genes have been previously validated experimentally by luciferase assays and gain of function experiments (Table S3) .
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Validation of the microarray analysis in cell lines and primary AML patients
To validate the microarray data, we assayed the expression of three genes (MCL-1, CXXC6
and CDK6) by qRT-PCR and Western Blotting. We chose to validate CXXC6 because it was the most down-regulated miRNA after miR-29s transfection (Table S3) . CXXC6, a member of a novel protein family, is fused to mixed lineage leukemia (MLL) in AML containing the t(10;11)(q22;q23).
27 MCL-1 and CDK6 were chosen because both are oncogenes up-regulated in AML and play a key role in cancer apoptosis and cell cycle, respectively. (Figure 4F) . These results were also reproduced in three primary AML samples. As shown in Figure 4G , CXXC6, CDK6 and MCL-1 mRNA levels were lower in miR29b transfected samples with respect to the controls at 24 hs ( Figure 4G and S2) . Furthermore, 
Target validation by luciferase assays
To validate these interactions, we cloned the 3'UTR of MCL-1, CXXC6 and CDK6 predicted to interact with miR-29 ( Figure 5A, B and C) into a luciferase reporter vector and co-transfected with miR-29b into K562 cells (Figure 5D ). According to TargetScan inverse correlation 325 probes (266 genes) and positive correlation 331 probes (281 genes) (P<0.01) ( Table S5 ). About 42% of the miR-29a correlated genes were also correlated with miR29b (274 from 656 probes).
Gene Ontology (GO) analysis of genes regulated by miR-29a and -29b in primary AML samples
Genes found negatively correlated with miR-29a and -29b in primary AML samples were analyzed with DAVID functional Annotation tool to identify GO categories most represented in this subset ( Table 2) . 24 Consistent with the cell line data, these results show that expression of miR-29a and -29b directly or indirectly affect the expression of apoptosis related genes ( Table   2 ). However, there were some differences between the miR-29a and -29b signatures. For example, several GO terms related to protein metabolism processes, such as post-translational protein modification, biopolymer modification and protein modification process were found over-represented only in miR-29b correlated genes ( Table 2) . Likewise, GO terms related to immune function, such as defense response, inflammatory response and response to wounding were enriched only in miR-29a correlated genes ( Table 2) . We also analyzed GO categories
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From most represented in genes that were positively correlated with miR-29b. Interestingly, we found a significant enrichment of genes belonging to RNA regulation and gene transcription, including; RNA metabolic process, regulation of nucleic acid metabolic process, gene expression, and regulation of transcription ( Table 2) . No GO categories were enriched in genes positively correlated to miR-29a. 
Mcl-1 protein expression is inversely expressed to miR-29b in primary AML samples
MiR-29a and -29b are down-regulated in primary AML samples with monosomy 7
Since, the miR-29b-1/miR-29a cluster is located in chromosome 7 (7q32) (Figure 6B ) we hypothesized that primary AML samples with genomic loss of this region (e.g. monosomy 7) may express low miR-29a and 29b levels. Therefore, we analyzed miR-29a, -29b and -29c expression in primary AML samples with monosomy 7 (n=8), either isolated or in context of other cytogenetic abnormalities, versus cases with other karyotype abnormalities (n=35) using qRT-PCR ( Table S6) . As shown in Figure 6C , miR-29a and -29b levels were lower in AML patients samples with monosomy 7 with respect to those with other karyotypes (miR-29a
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From P=0.0001 and miR-29b P=0.04, t-test). However miR-29c expression levels were not different between these two groups (P=0.07, t-test). MiR-29c resides on chromosome 1q32.2 ( Figure 6C ).
These results suggest that genomic deletion of the miR-29b-1/miR-29a cluster could be responsible for the loss of miR-29a and -29b expression in this subset of AML patients. Further studies with larger numbers of patients will be needed to confirm these intriguing results.
Discussion
The data presented here, indicate that forced expression of miR-29a and -29b in AML cell lines and in primary AML blasts inhibited cell growth and induced apoptosis. Interestingly, the antiapoptotic effect of miR-29s over-expression in AML cell lines was observed after 48 hours of transfection, while the anti-proliferative effect was noticed earlier at 24 hours. These results indicate that miR-29-dependent cell proliferation effects are not due to apoptosis, and are both likely to contribute to the tumor suppressor activity of these miRNAs. The tumor suppressor effect of miR-29b in AML was further demonstrated in vivo.
To characterize the miR-29 tumor suppressor function in leukemia and identify the pathways regulated by miR-29, we analyzed the expression changes in the K562 cell line after overexpressing miR-29a or -29b. This is an effective strategy to discover target genes and identify pathways regulated by miRNAs.
32-33 The results indicated that there is a significant enrichment for miR-29 predicted targets among the down-regulated genes after transfection of miR-29s.
Many of the down-regulated genes are involved in critical pathways such as apoptosis, cell cycling and proliferation. For example, miR-29a and -29b regulate critical antiapoptotic genes such as MCL-1. The Bcl-2 family is comprised of both pro-apoptotic and antiapoptotic proteins, We have also analyzed the correlation between miR-29a or -29b expression and mRNA expression in 45 primary AML samples. Consistent with the cell line data, apoptosis genes, such as MCL-1, were enriched in the primary blasts mRNAs that inversely correlated to miR-29a or29b expression levels. This result was also observed at the protein level in a few primary AML samples. However further studies using large numbers of primary AML samples will be needed to confirm this interaction.
Although there were common genes among the K562 cell line and the primary AMLs Affymetrix signatures, substantial differences were expected: first, the cell line profile was obtained shortly after ectopic expression of the miR-29s, while the primary AML samples
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Another interesting finding was the enrichment for genes involved in DNA transcription and RNA metabolism among the genes positively correlated only with miR-29b but not miR-29a.
Since miR-29b is also located in the nucleus 39 , miR-29b might directly regulate gene transcription by a different mechanism than RNA induced silencing complex (RISC) mediated protein translation inhibition and/or mRNA cleavage.
In conclusion, we demonstrate "in vitro" and "in vivo" that miR-29b is a tumor suppressor 
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